Topics

Articles

The deal features felzartamab, an investigational anti-CD38 monoclonal antibody, whose clinical outcomes have shown potential to tackle various immune-mediated diseases.

Biogen Agrees to Acquire HI-BIO for $1.15 Billion

The agreement is expected to focus on cell manufacturing processes, with potential for sharing tech with academia, startups.

Astellas, YASKAWA Sign Cell Therapy MoU Powered by Robotics Technology

The facility, company says, will be its first that covers end-to-end ADC production.

AstraZeneca to Build $1.5 Billion Antibody Drug Conjugates Manufacturing Plant in Singapore

The company increases its selection of atopic dermatitis treatments in the process.

Johnson & Johnson Purchases Proteologix for $850 Million

Leaders in the space discuss aspects of experimental drug support and more at this year’s US Pharma and Biotech Summit.  

Financially Supporting Pharma Innovation

A cohort study investigates how the use of a murine chimeric monoclonal antibody biosimilar—as opposed to the original biological drug—affects healthcare expenditures. 

The Influence of an Infliximab Biosimilar on Hospital Savings

IQVIA report explores the latest spending tendencies in the United States, while providing additional clarity as to why COVID-19 vaccines and therapeutics continue to experience a decline in volume.

The Current State of the Healthcare Industry’s Usage and Spending Trends

The acquisition, the parties say, will benefit pharma and biotech in the clinical and commercial stages. 

Myonex Finalizes Creapharm Deal

Collaboration will be oncology based—centered around allogeneic CAR-T cell therapy product candidates—and will provide Poseida with up to $550 million if certain milestones are met. 

Astellas, Poseida Therapeutics Ink Allogeneic Cell Therapy Agreement

Per the US strategic partnership agreement, the adalimumab high-concentration interchangeable biosimilar will be distributed under the Quallent Pharmaceuticals private label.

Business and Finance